HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical studies with d-fenfluramine.

Abstract
d-Fenfluramine (dF) (15 mg twice daily) has been studied in controlled trials in human obesity and has been shown to increase adherence to diet, to enhance its efficacy, and most importantly, to prevent weight regain when continued over 1 y. Few side effects, mostly transient, have been observed. A long-term use of dF in the management of some obese patients could be foreseen. Additionally, evidence that dF improves eating symptoms and dysphoric impairments in obese cravers, premenstrual syndrome, seasonal affective disorder, and smoking withdrawal syndrome has been presented.
AuthorsB Guy-Grand
JournalThe American journal of clinical nutrition (Am J Clin Nutr) Vol. 55 Issue 1 Suppl Pg. 173S-176S (01 1992) ISSN: 0002-9165 [Print] United States
PMID1728829 (Publication Type: Clinical Trial, Journal Article, Review)
Chemical References
  • Fenfluramine
Topics
  • Body Weight (drug effects)
  • Female
  • Fenfluramine (adverse effects, pharmacology, therapeutic use)
  • Humans
  • Obesity (drug therapy, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: